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Abstract  
 
Schizophrenia is considered to develop as a consequence of genetic and environmental 
factors impacting on brain neural systems and circuits during vulnerable 
neurodevelopmental periods, thereby resulting in symptoms in early adulthood. 
Understanding of the impact of schizophrenia risk factors on brain biology and behavior can 
help in identifying biologically relevant pathways that are attractive for informing clinical 
studies and biomarker development. In this chapter, we emphasise the importance of 
adopting a reciprocal forward and reverse translation approach that is iteratively updated 
when additional new information is gained, either preclinically or clinically, for offering the 
greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and 
treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform 
early intervention strategies prior to the development of schizophrenia. 
Given the emerging nature of this approach in the field, this review will highlight recent 
research of preclinical biomarkers in schizophrenia that show the most promise for 
informing clinical needs with an emphasis on relevant imaging, electrophysiological, 
cognitive behavioural and biochemical modalities. The implementation  of this reciprocal 
translational approach is exemplified firstly by the production and characterisation of 
preclinical models based on the glutamate hypofunction hypothesis, genetic and 
environmental risk factors for schizophrenia (reverse translation), and then the recent 
clinical recognition of the thalamic reticular thalamus (TRN) as an important  locus of brain 
dysfunction in schizophrenia as informed by preclinical findings (forward translation).   
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1. Introduction  
 
Contemporary thinking on the causes of schizophrenia is that a combination of genetic and 
environmental risk factors interact during neurodevelopment to disrupt neural processes 
which then give rise to a diverse range of symptoms that typically emerge in late 
adolescence. Despite recent advances in the identification of these risk factors, we are now 
only at the beginning of the journey to translate this information into identified biomarkers 
with utility that can be used to predict clinical outcome, disease progression, therapeutic 
responsiveness and to inform drug discovery.  Currently, diagnosis (via DSM 5 and ICD10) is 
based upon a descriptive collection of behaviours, that lack disorder specificity and show 
high heterogeneity, and treatments are based upon the dopamine hypothesis of 
schizophrenia developed over 60 years ago. Not surprisingly there is extremely limited 
scope at present for a personalised medicine approach in schizophrenia and in psychiatry in 
general. The identification of symptom domain relevant biomarkers would dramatically 
impact on our ability to diagnose and treat psychiatric disorders. For schizophrenia 
however, no biomarkers are currently adopted in clinical practice. Prata et al (2014) have 
reviewed the diverse literature on potential biomarkers for psychosis, noting that only one 
of hundreds of outcome prediction biomarkers demonstrated clinical utility; namely a 
pharmacogenetic biomarker that predicts the side –effects of clozapine (Prata, Mechelli and 
Kapur, 2014).  
Nonetheless, with recent advances in genetic, genomic, neural imaging, immunological, 
electrophysiological and cognitive neuroscience approaches, the path to developing 
biomarkers for schizophrenia continues, and is becoming increasingly refined. (See chapters 
by ; Lyndon-Staley and Bassett; Hunter and Lawrie; Herron, Nerurkar and Cavanagh this 
volume).  Indeed, a reliable diagnostic biomarker now exists for psychosis resulting from 
autoimmune limbic encephalitis which can occur as a result of autoantibodies to NMDA 
receptors. This diagnostic biomarker is in the form of a serum assay to detect anti-NMDA 
antibodies.  Whilst patients experiencing this form of psychosis represents a small 
percentage of those experiencing schizophrenia overall, the identification of this patient 
subgroup is important as the disorder is treatable particularly if identified early (see Herron, 
Nerurkar and Cavanagh this volume).  
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Key remaining questions include (a) how can preclinical research impact on the 
development of clinically relevant biomarkers?  (b) how can clinically identified biomarkers 
be effectively ‘reverse translated’ in preclinical models? and (c) how can these biomarkers 
be effectively utilized in preclinical research to improve the drug discovery process?  
 
First it is important to define biomarkers and highlight their clinical utility. Biomarkers are 
objective biological measures that can broadly be divided into several categories: a) 
diagnostic - where they can aid in predicting risk and diagnosis b) prognostic - where they 
can provide a signpost for clinical course and c) predictive of drug response/therapeutic 
intervention - whether beneficial or adverse, and thereby provide a potential means of 
patient stratification. 
 
There is of course, the theoretical potential for biomarkers to overlap in clinical utility; a 
diagnostic biomarker might not only be a marker for a particular symptom of the disorder 
but may also be a marker for treatment response. Moreover, given the overlapping 
biological basis and symptom profile of different psychiatric disorders it is likely that some 
biomarkers may be relevant across the traditional diagnostic boundaries. Given this, and the 
diverse range of symptoms present in schizophrenia, it is likely that a select panel of 
biomarkers will be required for effective diagnostic, prognostic and therapeutic 
intervention.   
 
In this chapter we provide a brief overview of the current status of biomarkers in preclinical 
schizophrenia research. We then focus on the importance of forward and reverse 
translation approaches for biomarker development with specific recent advances in the 
areas of brain imaging, brain network connectivity, oscillations, behavioural analysis and 
biochemical research that are increasing our understanding of disease risk and aetiology 
and how they could be used for identifying novel effective treatments. 
 
 
 
2. Current status  
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In order for preclinical biomarkers to translate to a clinically relevant outcome they should 
be measured in preclinical models of translational value and high validity.  The preclinical 
model should encompass a relevant feature of the disorder (e.g. a genetic variant) and the 
measurement taken (the biomarker in this case) should be of clinical relevance. 
 
Historically, preclinical models relevant to schizophrenia have been based upon whether 
they fall into the category of construct, face and predictive validity.  Given that the causes of 
schizophrenia are multifactorial and not fully established, full construct validity is not yet, 
and is arguably unlikely to ever be fully, achievable in a single specified animal model.  
Nevertheless, recent advances in the understanding of the genetics of schizophrenia have 
enabled models of higher construct validity to be generated, with the caveat that relatively 
few of the genetic hits are simple single gene loss of function variants. Furthermore as our 
knowledge of the multifactorial basis of the disease increases, so does our ability to 
integrate multiple aetiologically relevant mechanisms into one preclinical model, as 
exemplified by recent studies combining genetic and environmental risk factors ((Nagai, Ibi 
and Yamada, 2011; Ayhan, McFarland and Pletnikov, 2016; Moran et al., 2016).  Hence, the 
construct validity of the preclinical models used in the field is increasing. 
Models with face validity and predictive validity have typically been most widely employed 
for drug discovery. Face validity applies to many behavioural tasks including sensorimotor 
gating as measured by prepulse inhibition (PPI), where similar phenomenon can be 
observed in humans and rodents.  Indeed, reversal of rodent PPI deficits by antipsychotic 
drugs also supports the potential predictive validity of this behavioural model (Swerdlow 
and Geyer, 1998; Martinez et al., 2000; Leng et al., 2003; Clapcote et al., 2007) in that these 
antipsychotic drugs can ameliorate the positive symptoms of schizophrenia. However, the 
evidence for antipsychotic drugs actually reversing  PPI deficits in humans is less 
substantiated (Mackeprang, Kristiansen and Glenthoj, 2002; Duncan et al., 2003). This raises 
the question of whether the phenomenon of PPI is measuring similar neurobiological 
processes in rodents and humans. Arguably, a key element of face validity is to establish 
readouts that index the relevant neural circuitry across species. In addition, PPI deficits are 
not specific to schizophrenia, being present in a broad range of other brain disorders 
including Alzheimer’s, Parkinson’s and Huntington’s disease (Swerdlow et al., 1995; Perriol 
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et al., 2005) and there is a great degree of overlap in performance between individuals in 
clinical and healthy samples, limiting the diagnostic potential of PPI as a biomarker for 
schizophrenia.   
 
In terms of drug discovery, existing models have been of value in predicting antipsychotic 
drugs that ameliorate the hallucinations and delusions that form the positive symptoms of 
schizophrenia and for predicting extrapyramidal motor side-effects.  However, these models 
have tended to identify drugs with the same mechanism e.g D2 receptor blockade. From a 
clinical perspective, there is considerable room for improvement as antipsychotic  drugs are 
not always effective, do not cure the disease and have many side effects.  In the past 20 
years, it has become apparent that the cognitive deficits and negative symptoms of 
schizophrenia are major factors in determining patient functionality/outcome and quality of 
life (Green et al., 2000; Green, Kern and Heaton, 2004; Nuechterlein et al., 2011; Fervaha et 
al., 2014).  Despite substantial investment by the pharmaceutical industry, no effective 
treatments have emerged for cognitive deficits and negative symptoms (Dunlop and 
Brandon, 2015).  
 
Arguably this largely results from the limited construct validity of existing models combined 
with the use of ‘biomarker’ measures in animal models that do not translate to the clinic  or 
which only replicate previous mechanisms (Pratt et al., 2012). As a result of this 
translational bottleneck, new approaches to improve translation are underway. 
 
3. Forward and Reverse Translation  
 
The lack of biologically informed diagnosis for schizophrenia presents a significant challenge 
for developing preclinical biomarkers.  It has been argued that the diagnostic frameworks of 
DSM and ICD provide information on syndromes making it unlikely that any biomarker will 
associate with these descriptors (Scarr et al., 2015).  Instead, it is more likely that 
biomarkers will align with particular symptoms present in a subpopulation of individuals and 
which may cross current diagnostic boundaries (Scarr et al., 2015; Clementz et al., 2016). 
This ethos of striving for stratification forms the basis of a recent classification scheme 
proposed by the US National Institute of Mental Health (NIMH) termed Research Domain 
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Criteria (RDoC). A ‘new way of classifying mental disorders based on dimensions of 
observable behavior and neurobiological measures’ (http://www.nimh.nih.gov/research-
priorities/rdoc/index.shtml).   
From a preclinical perspective, the RDoC approach of seeking to identify genes, molecules, 
brain circuits and physiological measures associated with specific behavioural constructs 
offers opportunities to more effectively align translation in the search for biomarkers.  
Another initiative, CNTRICS (Cognitive Neuroscience Treatment Research to Improve 
Cognition in Schizophrenia) has the goal of ‘’developing measurement approaches from 
cognitive, social and affective neuroscience so that they may be implemented in efforts to 
develop treatments for impaired cognition in schizophrenia’’(http://cntrics.ucdavis.edu/).  
CNTRICS was developed in order to apply advances in cognitive neuroscience to the clinic, 
moving beyond the previously used standardized tests to those that could investigate 
specific cognitive constructs. An important outcome of CNTRICS has been the identification 
of cognitive tasks that can be implemented in parallel in animal models (Dudchenko et al., 
2013a; Lustig et al., 2013a; Moore et al., 2013).   Moreover, integrating this information 
with neural imaging findings is a key goal.   
Together RDoC and CNTRICS form a feasible clinical approach to inform the development of 
preclinical models and the identification of biomarkers.   For example, working memory 
deficits have been related to dysfunctional prefrontal cortex activity (Perlstein et al., 2001; 
Manoach, 2003; Potkin et al., 2009; Kauppi et al., 2014; Senkowski and Gallinat, 2015; Van 
Snellenberg et al., 2016) in schizophrenia and other psychiatric disorders. This not only 
paves the way for developing clinical biomarkers but importantly offers the opportunity for 
effective ‘Reverse translation’ in the sense that preclinical models could adopt similar 
imaging and behavioural measures. Moreover, preclinical research can help to identify the 
genetic, cellular and environmental mechanisms that contribute to these deficits using 
identified cognitive tasks and imaging modalities, thereby providing ‘biomarker’ tools to 
discover new treatments and predict which treatments might prove most effective in a 
subset of patients.  Notably this strategy would be helpful for identifying treatments to 
improve a particular cognitive construct rather than the disorder as a whole and may of 
course cross existing diagnostic boundaries.  A further benefit of preclinical research is that 
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it can directly inform clinical research through the more classically accepted paradigm of 
‘Forward translation.’ For example, current clinical imaging techniques provide less 
anatomical resolution and cellular specificity than preclinical imaging.  Hence novel brain 
regions, cells and circuits identified preclinically, can be taken forward to investigate 
potential clinical biomarkers in patients. Of course, the most broadly recognized paradigm 
of ‘Forward translation’ is that of preclinical drug validation prior to clinical testing. A 
historic lack of ‘Reverse translation’ in the context of schizophrenia preclinical drug 
discovery has been a major limiting factor in effective ‘Forward translation’ in this regard. 
Adopting a reciprocal forward and reverse translation approach, that is iteratively updated 
when additional new information is gained offers the greatest opportunity for discovering 
panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia.  
In this chapter, we review recent research on preclinical biomarkers that show most 
promise for informing clinical need. In this context we focus on relevant imaging, 
electrophysiological, cognitive and biochemical modalities in preclinical models 
based upon the glutamate hypothesis and genetic and environmental risk factors 
(reverse translation). We then discuss one example of productive forward and 
reverse translation in the use of acute ketamine in human volunteers and in rodents. 
Finally, we provide an example of the importance of forward translation, which has 
revealed the thalamic reticular nucleus (TRN) as an important locus of brain 
dysfunction in schizophrenia. 
Insert Fig 1 here:  ‘Framework for biomarker development through the adoption of forward 
and reverse translation approaches’. 
 
4. Reverse Translation: Imaging Biomarkers 
 
4.1  Glutamate and hypofrontality  
 
The glutamate hypothesis of schizophrenia is based upon the observations that NMDA 
receptor antagonists such as phencyclidine (PCP) and ketamine can induce the positive and 
negative symptoms of schizophrenia together with cognitive deficits in normal volunteers 
which are exacerbated in schizophrenia ((Javitt and Zukin, 1991; Krystal et al., 1994). In 
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addition, individuals who chronically abuse PCP show cognitive deficits that are similar to 
those seen in the disorder (Cosgrove and Newell, 1991). The search for the underlying 
biological mechanisms has revealed changes in expression of glutamatergic synaptic 
markers in post mortem brain (Meador-Woodruff et al., 2003) as well as corresponding 
genetic evidence (e.g. GRIN1, GRIN2A-D association) (Demontis et al., 2011; Ripke et al., 
2014; Harrison, 2015; Hu et al., 2015). Importantly both common and rare genetic risk 
factors for schizophrenia, including copy number variants,  exert a biological impact on the 
glutamatergic synapse ; including the postsynaptic density associated with the NMDA 
receptor complex (Pratt et al., 2012; Morris and Pratt, 2014; Pocklington, O’Donovan and 
Owen, 2014; Hall et al., 2015; Harrison, 2015; Reddaway et al this volume ).  
 
Although, there is accumulating evidence for an impact of schizophrenia genetic risk upon 
the glutamatergic synapse, the huge investment in NMDA receptor anatagonist models, 
particularly for drug discovery, began ~30 years years ago.   This was largely based upon the 
observational findings that NMDA receptor antagonists, can induce symptoms resembling 
schizophrenia in normal subjects, which are exacerbated in schizophrenia ((Jentsch and 
Roth, 1999; Morris, Cochran and Pratt, 2005; Large, 2007; Jones, Watson and Fone, 2011; 
Pratt et al., 2012)).  The behavioural, neurochemical and brain imaging deficits identified in 
these models provide translational biomarkers for discovering new treatments.  It is 
important to recognize that no single NMDA receptor model exists.  Acute, subchronic and 
chronic drug treatment regimens have been utilized and a diverse range of standard of care 
and novel drugs have been evaluated for their ability to restore a range of rodent 
behaviours.  As an existing example of forward translation in schizophrenia, studies 
performed in these models were key in the  assessment of mGlu2/3 receptor agonists for 
the disorder,  but unfortunately these drugs did not show a clear clinical benefit in recent 
trials(Patil St et al., 2007; Dunlop and Brandon, 2015). Several factors may have explained 
this disappointing finding including trial design, the outcome measures taken and patient 
selection.  From a preclinical perspective, the lack of predictive validity could be in part be 
explained by the use of behavioural measures that do not align with CNTRICS, coupled with 
the NMDA receptor model itself (with variables such as drug dose, acute treatment, chronic 
treatment, treatment with washout, assessments in the presence or absence of drug 
contributing to the inconsistent results).  Interestingly, an investigation of a range of NMDA 
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receptor antagonists in rodent cognitive tests has shown inconsistent results across tasks 
with no common deficits produced by all drugs investigated. (Smith et al., 2011). 
Furthermore, it has been argued that there does not seem to be an NMDA receptor 
antagonist regime that engages NMDA receptors equivalently in humans and animals that 
reliably produces the same cognitive deficits in each species (Gilmour et al., 2012).   In 
addition, we do not yet understand how and when abnormal glutamate transmission 
develops in schizophrenia, hence acute and repeated NMDA receptor antagonist treatment 
models in rodents are likely to reflect different stages of the disorder.  
 
With these caveats in mind, an alternative approach is to explore ‘intermediate’ 
phenotypes, lying between a disease-relevant mechanism and the behavioural outcome, 
and ‘endophenotypes’, lying between an established genetic risk factor for the disease and 
the behavioural outcome. As these intermediate and endophenotypes lie on the path 
between the basic biology of the disorder and its symptoms they could potentially be more 
robust and useful, in comparison to behavioural outcomes, in aiding the discovery of 
schizophrenia biomarkers. Imaging biomarkers fall into this category and we have therefore 
focused on developing a model based upon the clear evidence that prefrontal cortex activity 
is disrupted in schizophrenia (Lewis et al., 1999; Hill et al., 2004; Potkin et al., 2009). Using a 
low dose repeated PCP treatment regime with a washout period, we demonstrated 
hypofrontality ( Cochran et al., 2003; Dawson et al., 2012) mirroring that observed in 
schizophrenia.  This imaging deficit was accompanied by deficits in markers of GABAergic 
function, namely reduced parvalbumin and Kv3.1 mRNA expression and importantly deficits 
in cognitive flexibility as measured by the CNTRICS recommended translationally relevant 
attention-set shifting task (Cochran et al., 2002; Cochran et al., 2003; Egerton et al., 2008; 
Pratt et al., 2008).  
Hence imaging ‘hypofrontality’ could be an important preclinical biomarker for discovering 
drugs to ameliorate cognitive deficits, particularly in relation to the executive cognitive 
deficits, present in schizophrenia.  Current antipsychotic drugs have minimal impact on 
restoring cognitive deficits in patients and predictably clozapine and haloperidol did not 
restore hypofrontality in this model.  Similarly, PCP-induced deficits in cognitive flexibility 
are not reversed by haloperidol or risperidone in a rodent repeated PCP model 
(Goetghebeur and Dias, 2009).  This further supports the mechanistic and translational 
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validity of this model; avoiding the generation of false-positive drug effects in preclinical 
models is central to ensuring their translational validity.  
 
4.2 Glutamate and functional connectivity  
 
Non-invasive imaging technologies have enabled the identification of brain regions, such as 
dysfunctional activity of the prefrontal cortex (PFC) in schizophrenia.  Nevertheless, it is 
clear that the PFC does not act in isolation and exhibits multiple complex neural interactions 
within and beyond the PFC.  Recent advances in the field of network science are enabling 
this complexity to be defined. Hence, in the clinical literature there has been huge interest 
in understanding the alterations in structural (anatomical) and functional brain network 
connectivity that are present in patients with schizophrenia, and how these relate to specific 
symptom domains in the disorder. These studies provide valuable new insight into how 
interactions between brain regions and neural subsystems are disturbed in the disorder and 
have the potential to be developed as imaging biomarkers (See Lydon-Stanley and Bassett 
this volume) . When utilized in combination with specific cognitive tasks these approaches 
can also give valuable insight into how these disturbed interactions contribute to the 
cognitive deficits present in schizophrenia (Nieuwenstein, Aleman and De Haan, 2001; 
Forbes et al., 2009). Overall, these studies are generally supportive of reduced functional 
brain network connectivity on the global scale (Micheloyannis et al., 2006; Liu et al., 2008; 
Lynall et al., 2010; van den Heuvel et al., 2010; A Fornito et al., 2011), and between defined 
neural systems (Schlösser et al., 2003; Benetti et al., 2009; Deserno et al., 2012) in patients 
with chronic schizophrenia. The most consistently defined alterations in neural system 
connectivity include reduced frontal cortex connectivity (van den Heuvel et al., 2010; Alex 
Fornito et al., 2011; Camchong et al., 2011; Pettersson-Yeo et al., 2011; Roiser et al., 2013) 
with a prominent reduction in hippocampal-frontal cortex functional connectivity     (Meyer-
Lindenberg et al., 2005; Zhou et al., 2007; Godsil et al., 2013), and compromised thalamic 
connectivity (Welsh, Chen and Taylor, 2010; Tomasi and Volkow, 2014).  Many of these 
alterations appear to be conserved in patients with first episode patients (Zhou et al., 2007; 
Benetti et al., 2009; Schmidt and Borgwardt, 2013) and in at risk individuals (Dauvermann et 
al., 2013; Schmidt et al., 2014) suggesting that they are not merely the consequence of 
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chronic antipsychotic treatment, which has also been shown to independently impact on 
brain functional connectivity (Cole et al., 2013). 
 
From a drug discovery perspective, it is hoped that the alterations in brain network 
connectivity seen in patients represent an intermediate phenotype/endophenotype, and 
thus a useful biomarker, that will be both responsive to pharmacological intervention and 
whose correction/restoration would closely align with the improvement of specific disease 
symptoms. Of course, there is also great interest in using brain network functional 
connectivity as an intermediate phenotype in the preclinical drug validation process 
(Dawson, Morris and Pratt, 2015) for further review). Therefore, an essential first step in the 
process has been to reverse translate some of the analytical approaches used in the clinical 
literature to quantitatively define brain network connectivity and to apply these to brain 
imaging data gained in preclinical models relevant to the disorder.  If found to be 
successfully conserved in translationally valid preclinical models these alterations in brain 
network connectivity should represent effective biomarkers against which the efficacy of 
novel drugs can be tested, in combination with other experimental approaches including 
relevant behavioural assessment and biochemical analysis. Moreover, if assessed in 
combination with translationally relevant behavioural paradigms (recommended by 
CNTRICS) these functional connectivity biomarkers could potentially be used to stratify 
patients and predict treatment response in clinical populations. Importantly, many of the 
functional connectivity alterations present in patients also appear to be conserved in 
individuals with mutations in specific candidate risk genes or CNV’s for the disorder  
(Esslinger et al., 2009; Callicott et al., 2013; Padula et al., 2017), suggesting that these 
alterations in brain network connectivity represent a useful endophenotypic biomarker in 
the disorder. Given that preclinical models based on established genetic risk factors for 
schizophrenia represent a key translational approach, with high construct validity, assessing 
the alignment of alterations in brain network connectivity present in these models and in 
humans with relevant risk gene mutations is likely to be central in establishing the utility of 
this approach. It is important to note that this area of research is in its infancy, but the 
emerging data support its potential validity. Intriguingly, the alterations in connectivity 
currently reported appear to be both conserved across species (ie. between humans and 
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rodents) and across imaging modalities (ie. 2-DG, fMRI, EEG, electrophysiology, MEG, 
(Dauvermann, Lee and Dawson, 2017; Pratt et al., 2017) 
 
A leading exemplar of reverse translation in this context is the characterization of functional 
brain network connectivity in preclinical models based on glutamate system hypofunction. 
For example, characterization of altered functional brain network connectivity in the 
subchronic PCP model supports reduced connectivity at the global scale along with a 
reduction in hippocampal-prefrontal connectivity, reduced thalamo-prefrontal and reduced 
thalamic nuclei connectivity overall (N. Dawson et al., 2012, 2014). These results were 
gained by analyzing 14C-2-deoxyglucose autoradiographic functional brain imaging data 
using graph theory algorithms and other analytical approaches (namely the partial least 
squares regression (PLSR) algorithm) that have previously been applied to functional brain 
imaging data gained in humans (McIntosh and Lobaugh, 2004; Micheloyannis et al., 2006; 
Liu et al., 2008). The validity of this approach is further supported by the observation that 
subchronic treatment with the NMDA receptor antagonist memantine also reduces 
hippocampal-PFC connectivity in rodents, as assessed using fMRI (Sekar et al., 2013). 
Emphasising the translational relevance of the alterations in functional connectivity seen in 
the subchronic PCP model, the global network alterations seen in the model are consistent 
with the altered neural systems connectivity, including reduced hippocampal-PFC and 
thalamic connectivity, seen in patients with schizophrenia (Micheloyannis et al., 2006; Liu et 
al., 2008; Godsil et al., 2013; Anticevic et al., 2014).  Moreover, the potential translational 
relevance and the utility of these alterations as biomarkers in the drug validation process is 
supported by evidence that these alterations in functional connectivity, including 
hippocampal-PFC and thalamo-PFC connectivity, are amenable to pharmacological 
correction by a drug, modafinil, known to have procognitive effects in both the subchronic 
PCP model and patients with schizophrenia (Goetghebeur and Dias, 2009;  Dawson et al., 
2012; Scoriels, Jones and Sahakian, 2013).  In addition, modafinil both increases PFC 
cerebral metabolism in schizophrenia patients and reverses the hypofrontality seen in the 
PCP model (Spence et al., 2005; Dawson et al., 2012), supporting PFC hypometabolism as a 
biomarker for the cognitive flexibility deficit seen in the disorder. 
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4.3 Emerging data in genetic, environmental and neurodevelopmental models relevant 
to schizophrenia 
 
More recently the approach of characterizing brain network connectivity in preclinical 
models relevant to schizophrenia has been extended. To date, this includes the 
characterization of connectivity alterations in genetic models relevant to the disorder, 
including the Df(16)A+/- mutant mouse model of the 22q11.2 microdeletion, which increases 
the risk of developing schizophrenia by ~20 fold , and mouse models based on the 
psychiatric risk gene Disrupted-in-Schizophrenia-1 (DISC1), which increases the risk of 
developing a major mental illness by ~ 50 fold; (Brandon et al., 2009). In both of these 
models reduced hippocampal-PFC connectivity is supported (Sigurdsson et al., 2010; 
Dawson, Morris and Pratt, 2015). While the findings from the Df(16)A+/- model are limited to 
the electrophysiological characterization of hippocampal-PFC connectivity, the analysis of 
brain network connectivity in the Disc1 mouse models from 14C-2-DG brain imaging data has 
allowed the more extensive systems-level analysis of alterations in functional brain network 
connectivity, that also identified altered thalamo-PFC connectivity as a consequence of 
Disc1 truncation (Dawson et al., 2015). Importantly, the reduced hippocampal-PFC 
connectivity identified through the analysis of functional brain imaging 14C-2-DG data has 
been confirmed using electrophysiology, proving the validity of this approach. In addition to 
these genetic risk factor models, reduced hippocampal-PFC connectivity is also evident in a 
model of environmental risk (maternal immune activation; MIA (Lisman and Jensen, 2013)) 
(Dickerson, Wolff and Bilkey, 2010) and a model of impaired neurodevelopment  (using the 
mitotic toxin methylazoxymethanol acetate; MAM) ( Phillips et al., 2012; Belujon, Patton 
and Grace, 2013). To date, the analysis of connectivity in these animals has been limited to 
electrophysiological characterisation of the hippocampus-PFC. Future systems-levels 
analysis of the functional connectivity alterations present in the brains of these animals, 
gained for example through the analysis of brain imaging data, could be used to identify 
how global network properties are altered in these models, other relevant neural system 
interactions that are compromised in these models, and their translational relevance to 
schizophrenia. 
 
5. Reverse Translation: Oscillations  
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The co-ordination of cortical and subcortical neuronal networks is achieved by neural 
oscillations. Such oscillations can be detected by electroencephalography (EEG) and 
magnetoencephalography (MEG) and represent synchronous activity of a population of 
neurons. These neuronal oscillations serve to integrate sensory processing with cognitive 
and motor outcomes and operate across many spatial and  temporal scales (Uhlhaas and 
Singer, 2010; Buzsáki and Watson, 2012; Lisman and Jensen, 2013).  Oscillatory activity 
occurs over a range of frequency bands from slow delta (0-4Hz) through to fast gamma (30-
80Hz). In schizophrenia, there are alterations in delta, theta and gamma power and 
impaired cross-frequency coupling between gamma and the slower frequency bands (theta 
and alpha).  The disruption in gamma oscillations has been a particular research focus with 
evidence for an involvement in dysfunctional neurocognition and perceptual disturbances in 
schizophrenia  (see (Gandal et al., 2012; Gonzalez-Burgos, Cho and Lewis, 2015; Pittman-
Polletta et al., 2015; Uhlhaas and Singer, 2015) 
 
Hence gamma oscillatory activity may represent a potential biomarker for studying 
pathophysiological processes, illness progression and therapeutic interventions.  To this 
end, deficits in gamma oscillatory activity are reported at first episode pyschosis, in 
unmedicated patients and to some degree in unaffected relatives.  Taken together this 
suggests that abnormal gamma synchrony is a heritable feature of schizophrenia and 
represent a neural endophenotype  (Gandal et al., 2012). It is important to note that gamma 
oscillations are found in the majority of mammalian brain structures and appear to be 
phylogenetically conserved in their sensory co-ordinating role.  This enables both forward 
and reverse translational research. 
 
Informed by clinical research, preclinical researchers are probing the neural mechanisms 
underpinning oscillations. Inhibitory GABA interneurons, which vary in structure, function 
and location in cortical layers and circuits are key to the generation of oscillations. Of 
particular interest for the production of gamma oscillations are the fast spiking parvalbumin 
(PV) containing GABA interneurons. PV interneurons of the basket cell subtype synapse on 
the cell body and proximal dendrites of pyramidal cells, whereas the chandelier cell subtype 
synapse at the initial axon segment of the pyramidal cells, thereby influencing pyramidal cell 
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activity (Gonzalez-Burgos, Cho and Lewis, 2015).  A range of pyramidal cell glutamatergic 
receptors (AMPA, NMDA and mGlu) are involved in regulating oscillations, along with NMDA 
receptors present on PV containing interneurons. Whittington’s group have probed the 
mechanisms of cortical gamma rhythms in vitro and shown that the generation of rhythms 
exists in three distinct forms.  In all three cases the gamma rhythm is an emergent property 
of a local neuronal network. The differences depend on the interneurons recruited (basket 
vs chandelier), pyramidal cell involvement and fundamental dynamic properties 
(Whittington et al., 2000, 2011). Arguably, the Pyramidal Interneuron Network Gamma 
(PING) model is likely to be particularly relevant to schizophrenia. In this model, a strong 
inhibitory input from PV containing basket cells would transiently silence the activity of a 
local population of asynchronously firing pyramidal neurons.  Once the inhibitory effect has 
subsided the pyramidal cells fire in synchrony.  Whittington et al (Whittington et al., 2000, 
2011) have shown that if this GABAergic inhibition is rhythmic at gamma frequency then the 
pyramidal cell activity also becomes rhythmic and this leads to synchronous gamma 
oscillations in the network. One hypothesis is that the reduced gamma power observed in 
schizophrenia could result from two aberrant processes 1) excitatory inputs to pyramidal 
cells are normal but feedback inhibition from PV interneurons is weak 2) excitatory drive to 
pyramidal cells is low because of a reduced number of dendritic spines. This in turn leading 
to a compensatory reduction in strength of feedback inhibition from PV basket cells 
(Gonzalez-Burgos, Cho and Lewis, 2015). 
 
There is a growing body of evidence that gamma oscillations are disrupted in preclinical 
models of relevance to schizophrenia.  These include models based upon neurotransmitter 
system dysfunction and established genetic risk factors.  The disruption of GABAergic 
circuitry could be a common pathway leading to gamma oscillation disturbances seen in 
these models.  In models based upon the glutamate hypothesis of schizophrenia, acute 
NMDA receptor blockade (PCP, ketamine) leads to increased gamma power (Phillips et al., 
2012) arguably through reduced GABA release onto pyramidal neurons following increased 
pyramidal cell activity after NMDA receptor blockade on GABAergic interneurons 
(Homayoun and Moghaddam, 2007). Furthermore, selective deletion of the NR1 subunit 
from PV positive neurons increased gamma power and resulted in deficits in spatial and 
working memory (Korotkova et al., 2010).  
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Models that reflect chronic disruption of NMDA receptor activity include repeated PCP 
administration and NMDA-NR1 neo-/- (NR1-/-) mice, which express less than 10% of 
obligatory NMDAR1 subunit. Repeated NMDA receptor blockade with PCP, altered theta 
power but not gamma power whereas NR1-/- mice showed an increase in baseline gamma 
power (similar to acute PCP) and disrupted gamma-theta band cross frequency phase-
coupling between hippocampus and prefrontal cortex (Dzirasa et al., 2009). This suggests 
that the temporal dynamics of NMDA receptor blockade, or neuroplastic/developmental 
events related to a chronic reduction in NMDA receptor activity, have a profound influence 
on the emergent effects of NMDA receptor hypofunction on cortical oscillations. 
 
In a genetic mouse model of the human 22q11.2 microdeletion, Df(16)A+/- mice showed 
reduced in vivo synchrony between the prefrontal cortex and hippocampus during a 
working memory task, although theta activity was the focus of this study, there was a trend 
for gamma activity  be reduced (Sigurdsson et al., 2010). Further support for gamma 
oscillation dysfunction in preclinical models relevant to schizophrenia is reviewed in (Gandal 
et al., 2012). In summary, disruption of oscillatory activity in preclinical models of 
schizophrenia risk factors shows some support for altered gamma activity as a common 
deficit across models.  Future work to characterize the neurobiology of these neural 
oscillations, and compare with findings in patients, is necessary.  Potentially this 
translational research could lead to patient stratification and inform drug discovery 
strategies. For example, novel compounds that target specific GABA interneurone markers 
could be assessed for efficacy in patients with a particular gamma oscillation characteristic 
and genetic phenotype. 
 
 
6. Reverse Translation: Behavioural biomarkers 
 
Historically, schizophrenia has been deconstructed into positive symptoms, negative 
symptoms and cognitive deficits.  As previously noted, despite the large impact on 
functional outcome, the negative symptoms and cognitive deficits are most resistant to 
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treatment and represent a large unmet clinical need (Green et al., 2000; Green, Kern and 
Heaton, 2004; Nuechterlein et al., 2011; Fervaha et al., 2014).  
Arguably one reason for the dearth of new compounds reaching the market to address this 
need is that preclinical behavioural studies do not adequately  access similar behavioural 
domains that are underpinned by similar brain circuitry to that recruited by human tasks 
(Pratt et al., 2012). In this section we focus on cognitive domains and briefly discuss positive 
and negative symptoms. 
 
6.1 Positive symptoms 
 
The delusions and typically auditory hallucinations of schizophrenia are those that are 
responsive (albeit not in all patients) to antipsychotic medication. Rodent models are 
considered a proxy marker at best of these symptoms.  Based upon the dopamine 
hypothesis of schizophrenia and aberrant dopaminergic transmission, these models typical 
measure amphetamine –induced hyperactivity (Van Den Buuse, 2010). In preclinical studies, 
current antipsychotic drugs show an ability to reverse amphetamine-induced hyperactivity 
and as such show some predictive validity. However, one major challenge to the 
translational validity of this approach is the concept of receptor tautology – the 
antipsychotics acting primarily as D2 receptor antagonists are simply antagonizing the D2 
activating effects of amphetamine administration, mediated through increased dopamine 
release. Thus, these studies prove the D2 receptor dependence of amphetamine-induced 
hyperlocomotion, rather than proving the therapeutic validity of these compounds in 
relation to the positive symptoms of schizophrenia. Moreover,  there is still scope for 
improved treatments for the positive symptoms of the disorder, primarily based upon the 
incomplete efficacy and side effect profiles of existing drugs.  For example, convincing 
arguments have been made that aberrant salience processes can explain the positive 
symptoms of schizophrenia (Kapur, Mizrahi and Li, 2005). Hence models that tackle this 
domain could prove useful.  Furthermore, increased understanding of the neural circuitry 
underpinning hallucinations may inform new model development. 
 
6.2 Negative symptoms  
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Negative symptoms are characterized by a range of sub-domains: affective flattening 
(reduced intensity and range of emotional expression), poverty of speech (alogia), 
anhedonia  and motivational deficits.  Sub-domains such as anhedonia and motivational 
deficits are readily accessible in rodent models and have been widely reviewed elsewhere 
(Millan et al., 2014; Felice Reddy, Horan and Green, 2016). Notably, with respect to 
anhedonia, the ‘liking’ of an experience is less impaired than the looking forward to a 
reward/pleasurable experience in schizophrenia. Arguably, rodent tasks that tackle the 
ability of an animal to work for a reward, such as the progressive ratio task, show better 
translation than tasks such as the sucrose preference task which relate more to the 
‘pleasurable experience’ (consummatory aspect). Additional tasks related to emotional 
processing (e.g. cognitive affective bias) also show great promise (See Emma Robinson this 
volume).  Nevertheless, as with cognitive deficits, drugs that ameliorate negative symptoms 
in rodent models have yet to translate into meaningful improvements of negative 
symptoms in patients. 
 
6.3 Cognition  
As noted earlier an important outcome of CNTRICS has been the identification of construct 
specific elements of human cognition that can be implemented in parallel in animal models 
((Young and Geyer, 2015)and MacQueen et al this volume). Table 1 summarises the 
recommendations made by CNTRICS for many of these cognitive domains. 
 
It is notable that many cognitive domains can be broken down into various components, 
known as constructs. For example, executive function comprises planning, problem solving, 
organisation, cognitive flexibility and inhibition of inappropriate responses.  CNTRICS have 
selected those components that are most affected in schizophrenia and which can be 
assessed in paradigms. In several cases, there are animal paradigms that can be considered 
as having good construct validity and which could be optimized further for development.  
Another important advance has been the introduction of automated operant touchscreen 
platforms in rodents for the measurement of multiple cognitive domains in settings similar 
to touchscreen tasks used in human cognitive assessments (Bussey et al., 2012; Oomen et 
al., 2013). 
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Insert Table 1 around here  
 
Whilst cognitive domains have been assessed in a range of models of risk factors for 
schizophrenia (Pratt et al., 2012; Moran et al., 2016) further work is required to establish 
the utility of genetic and genetic-environmental interaction models for schizophrenia drug 
discovery.  Nevertheless, a leading example of the drug discovery potential in a NMDA 
receptor antagonist model, is the finding that modafinil reverses PCP-induced attentional 
set-shifting deficits in rats (Goetghebeur and Dias, 2009; Dawson et al., 2012) , and 
improves attentional set-shifting in patients with schizophrenia (Turner et al., 2004). To 
date, however compounds which ameliorate cognitive deficits in rodent models and which 
translate into meaningful improvements in a patients’ quality of life are awaited.  
 
 In other domains, for example social cognition there are even larger challenges.  Social 
cognition is a particularly complex and multidimensional domain that also impacts on 
positive and negative symptoms (Millan and Bales, 2013). It encompasses our ability to 
interpret social signals, understand beliefs, intentions and actions thereby enabling 
appropriate behaviours in a social context.  Clearly translation to rodents is challenging, 
despite their sociable nature.  To this end CNTRICS have selected the general construct of 
social and emotional recognition (and appropriate response selection) as being appropriate 
to translate across species.  Tasks such as the social recognition/preference task are 
currently being widely used (Yang, Silverman and Crawley, 2011) although other tasks 
relevant to social behaviours warrant further investigation. Arguably, the concept of 
measuring social behaviours in a more naturalistic home cage setting offers improved 
translation. Indeed, such approaches are revealing differences in social behaviours in 
adolescent rodents treated with PCP and cage mates treated with saline (Mitchell et al 
2017).  Further work, to establish how genetic and environmental risk factors for 
schizophrenia impact on the development of social behaviours could conceivably show 
utility for drug discovery.  
 
Perceptual disturbances also feature strongly in schizophrenia. CNTRICS has identified ‘gain 
control and sensory integration’ as relevant constructs for assessment across species.  
Rodent paradigms such as pre-pulse inhibition (PPI) and mismatch negativity (MMN) have 
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been proposed to align with the human construct (Siegel, Talpos and Geyer, 2013; Young 
and Geyer, 2015), but at present there is not a clear consensus as to whether the same 
cognitive construct is being measured and other paradigms are awaited.  One candidate 
could be the recently developed mouse touchscreen task for global motion perception 
(Stirman, Townsend and Smith, 2016). 
 
7. Reverse translation: Biochemical biomarkers   
 
7.1 Imaging of neurotransmitter function 
 
Traditionally, schizophrenia has been viewed as reflecting dysfunction primarily of 
dopaminergic and/or glutamatergic neurotransmission. A substantial literature, stretching 
back over many years, covers in vivo imaging of various aspects of dopaminergic function. 
Current theories emphasise increased dopaminergic activity in the striatum, alongside 
reduced dopaminergic activity in cortical and limbic regions (Kambeitz et al., 2014; Slifstein 
et al., 2015; Weinstein et al., 2017). While these findings, derived from various different 
measures of dopaminergic function, appear to be robust, the effect sizes are small and 
insufficient for biomarker use. Nevertheless, future research into the causes of this 
divergent regulation of dopaminergic activity promises to provide important insight into the 
aetiology of the disease. 
 
More recently, some consensus has emerged concerning glutamate abnormalities in 
schizophrenia. Prefrontal cortical glutamate levels, as monitored via proton magnetic 
resonance spectroscopy (1H-MRS), appear to be decreased in patients with chronic 
schizophrenia although elevated anterior cingulate glutamatergic activity has been reported 
in several studies (Hugdahl et al., 2015; Merritt et al., 2016). Intriguing evidence suggests 
that the cingulate cortical changes, accompanied by reduced thalamic glutamate levels, may 
be present during the prodrome (Stone et al., 2009; Allen et al., 2015). While important 
mechanistically for understanding the disease process, again these effects have little 
imminent clinical biomarker potential. 
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Abnormalities in cortical glutamate transmission have however attracted attention as a 
translational biomarker at preclinical stages of drug development. A dramatic elevation of 
glutamate release in the prefrontal cortex, along with a surge in metabolic activity, is 
observed in adult rodents and humans following acute NMDA receptor blockade 
(Moghaddam et al., 1997; Miyamoto et al., 2001; Dawson, Morris and Pratt, 2013). This is 
suggested to result from disinhibition of prefrontal pyramidal neurons following blockade of 
tonically active NMDA receptors on the parvalbumin subtype of GABAergic interneurones 
(Homayoun and Moghaddam, 2007; Pratt et al., 2008) although an action at NMDA 
receptors on parvalbumin neurons may vary according to the stage of neurodevelopment 
(Rotaru, Lewis and Gonzalez-Burgos, 2012). Simultaneously, human volunteers experience a 
range of schizophrenia-related symptoms when treated with the NMDA receptor antagonist 
ketamine (Krystal et al., 1994). The enhanced glutamate release is postulated to be linked to 
the disease-relevant effects in humans and to behavioural deficits, most notably impaired 
PPI and increased locomotor activity, in rodents.  Hence there are rodent-human 
phenotypes apparently related to ketamine-induced cortical glutamate release which can be 
employed as biomarkers for drug development purposes (Javitt et al., 2018). 
 
7.2 Plasma biomarkers 
Many studies have searched for peripheral markers related to “state” or “trait” in patients 
with schizophrenia. It is probably fair to say that, to date, little has emerged of clear utility, 
whether for monitoring disease progression or treatment response, or for patient 
stratification during clinical trials. 
Patients with schizophrenia do tend to show altered levels of certain proteins in blood. 
Increased levels of C reactive protein (CRP) – generally indicative of immune system 
activation – are reliably detected in plasma of chronic patients (Miller, Culpepper and 
Rapaport, 2014; Fernandes et al., 2016), although this may not be the case at early stages of 
the disease (Dickerson et al., 2016). Meta-analyses consistently report elevations in plasma 
interleukin 1, soluble interleukin 2 receptor, interleukin 6 and TNF in patients (Potvin et 
al., 2008; Miller et al., 2011; Upthegrove, Manzanares-Teson and Barnes, 2014). Similarly, 
patient groups show reduced levels of the anti-inflammatory cytokine interleukin 10 (Zhang 
et al., 2017). This is frequently interpreted as a “smoking gun” indication of an abnormal 
response to a developmental immune challenge. However, this pattern of change in 
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immune mediators could alternatively reflect the expression of genetic risk factors, acting 
not only on neuronal circuit development to cause schizophrenia, but also on the peripheral 
immune system, and even potentially the gut microbiome (Schirmer et al., 2016), to perturb 
cytokine expression. In either case, the altered blood cytokine levels can be seen as a “trait” 
marker. The relatively subtle nature of the changes, and their obvious lack of specificity for 
schizophrenia, has precluded any exploitation as a biomarker. However, a blood-based 
multi-protein biomarker profile (including interleukin 10) has recently been proposed as a 
method for identifying at risk prodromal patients who are likely to transition to the full 
disease (Chan et al., 2015) hence representing a possible biomarker for disease progression. 
Arguably the most immediate prospects of exploiting plasma biomarkers may be in relation 
to patient stratification. There is some interest in anti-inflammatory agents as potential 
novel therapeutics in schizophrenia. In this regard, initial stratification of patient groups into 
those with and without a clearly elevated immune response profile might be useful. An 
immune-related biomarker for drug side-effect liability has also been suggested (Prata, 
Mechelli and Kapur, 2014) 
 
7.3 Gene expression   
Progress in development of novel drugs to treat Alzheimer’s disease has accelerated with 
the arrival of tools for in vivo imaging of the pathology of the disease, where this previously 
could only be assessed post-mortem. These imaging tools provide a rapid and direct readout 
of effects on disease progression. The ultimate aspiration would be to identify some similar 
tools for use in schizophrenia research.  This remains some way into the future, but we 
note, from evidence in post-mortem tissue, that decreased parvalbumin expression in the 
prefrontal cortex is a robust observation in patients with schizophrenia, with a substantial 
effect size, and possibly disease-specificity. A method for imaging parvalbumin neurones in 
vivo would undoubtedly represent a major advance in schizophrenia research. 
For further discussion of potential biochemical and gene expression  biomarkers see 
(Pickard, 2015)and Herron, Nerurkar and Cavanagh (this volume). 
 
 
8. Panels of Biomarkers 
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In the future it is likely that, both preclinically and clinically, a multiscale and integrated high 
dimensional approach to biomarker identification and utilization will be required to 
effectively impact on schizophrenia diagnosis, prognosis and treatment. For example, valid 
preclinical models will need to replicate, across a range of scales –molecular, biochemical, 
cellular, complex brain network and behavioral levels – core aspects of neural impairment in 
schizophrenia, to generate a suite of disease relevant biomarkers that can be maximally 
useful and predictive. Preclinical models based on aetiologically established risk factors, 
such as models based on glutamate system hypofunction and genetic risk factors combined 
with environmental insults during neurodevelopment, offer the greatest hope in this regard. 
Clinically, it is likely that advanced analytical approaches, such as machine learning, will play 
a key role in identifying and integrating information across a broad panel of biomarkers in 
order to have clinically relevant impacts for patients. Early studies have recently proven the 
diagnostic potential of machine learning approaches in relation to the analysis of brain 
imaging data (Salvador et al., 2017; de Witt et al., 2017), whose value could be further 
increased and refined through the inclusion of a greater range of biomarkers, including 
cognitive behavioural markers and polygenic risk scores. 
 
 
9. Forward Translation  
 
There is a general scepticism about the feasibility of modelling a disease as subtle and 
complex as schizophrenia in rodents. Unsurprisingly, there are few examples of successful 
forward translation, where data from preclinical models has informed understanding of the 
clinical disease or illuminated new routes to therapeutic treatments. One example of 
productive forward and reverse translation is the use of acute ketamine in human 
volunteers and in rodents. The ability of NMDA receptor antagonists, such as ketamine or 
phencyclidine, to produce symptoms of schizophrenia on acute administration in humans 
has led to many acute administration studies in rodents (Morris, Cochran and Pratt, 2005). 
Once it became clear that these drugs cause a profound increase in glutamate release and 
metabolic activity in the rodent prefrontal cortex ((Tamminga et al., 1987; Moghaddam et 
al., 1997; Duncan et al., 1999), then similar effects were confirmed in humans via imaging 
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studies (Lahti et al., 1995; Breier et al., 1997; Holcomb et al., 2000; Stone et al., 2012). The 
extent to which the elevated prefrontal glutamate release is responsible for the 
schizophrenia-like symptoms is still a matter of debate (Stone et al., 2012; Hugdahl et al., 
2015). Nevertheless, as mentioned previously, the directly comparable phenomena in 
rodents and humans can facilitate translation from preclinical to clinical arenas, for drug 
classes active in this model (Javitt et al., 2018).  
There is a further instance of forward translation that has only been validated recently and 
which demonstrates that rodent models can provide new insight into the human condition. . 
As noted above, we found that rats receiving chronic, intermittent low-doses of the NMDA 
receptor antagonist phencyclidine ( Cochran et al., 2003) develop metabolic hypofrontality 
and prefrontal cortex GABAergic interneuron deficits (reduced parvalbumin expression) that 
parallel those in the brains of patients with chronic schizophrenia. Importantly, chronic PCP 
administration to rats also reduced metabolic activity and parvalbumin in the thalamic 
reticular nucleus (TRN) ( Cochran et al., 2003) and the changes in the TRN actually preceded 
those in the PFC (Cochran et al., 2002) Indeed, since cortical parvalbumin expression is 
known to be regulated by the TRN (Alcantara, Soriano and Ferrer, 1996) we have proposed 
that the hypofrontality and PFC GABAergic deficits highly characteristic of schizophrenia (Hill 
et al., 2004; Molina et al., 2005; Lewis et al., 1999)) may be a consequence of TRN 
dysfunction. More recently we have identified TRN hypofunction and dysconnectivity in not 
only the PCP model relevant to schizophrenia (Dawson et al., 2012)but also following 
subanaesthetic ketamine administration (Dawson et al., 2014) and as a result of mutation in 
the Disc1 gene (Dawson et al., 2015) suggesting that TRN dysfunction may be a key 
mechanism in multiple preclinical models relevant to the disorder. In humans, the TRN is 
too narrow for resolution by current imaging techniques, and so any dysfunction in 
schizophrenia had not been detected. Remarkably, however, recent evidence, from analysis 
of post-mortem tissue, has now revealed that in schizophrenia there is a similar loss of 
parvalbumin expression in the TRN (Steullet et al., 2017).  Moreover, TRN dysfunction is also 
supported by observations in patients with schizophrenia of altered sleep spindle 
generation (Ferrarelli and Tononi, 2018). The fact that the rodent model was able to predict 
this pathological feature of the human disease clearly increases confidence in the 
translational value of other aspects of this and other relevant models model, be they 
cognitive, metabolic or neurochemical measures. Furthermore, the knowledge that 
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schizophrenia entails dysfunction of the TRN, and that this occurs at an early stage in the 
preclinical model, suggests new approaches to monitoring disease progression and 
treatment response clinically. Tracers for the selective imaging of the human TRN could be 
developed, based on existing knowledge of the neurochemistry of this region (Pratt and 
Morris, 2015). 
 
Summary  
 
Overall, in this chapter we have sought to highlight recent advances in the development of 
translational preclinical biomarkers for schizophrenia, with an emphasis of key work 
currently developing in this area. This includes leading examples of reverse and forward 
translation, the fruition of which is yet to be fully realized. In addition, we have highlighted 
key theoretical considerations at the forefront of current thinking in the field that focus on 
improving the translational value of preclinical models in this context, and the mechanisms 
of translation across the clinical-preclinical gap. Taking these approaches into consideration 
provides new hope for the advancement of biomarker identification in schizophrenia and 
the greater clinical impact of preclinical research in this area. 
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Cognitive 
domain  
Construct 
selected of 
relevance to 
schizophrenia 
Human  Rodent Tasks  References  
Attention  Control of 
attention 
(esp input 
selection) 
 
Ability to guide 
and refocus 
attention in 
accordance with 
internal goals and 
representations  
Continuous 
performance 
tasks 
5-Choice serial 
reaction time task (5-
CSRTT) 
 
5-choice continuous 
performance test (5-C-
CPT) 
 
Distractor condition 
sustained attention 
task (dSAT) 
 
 
 
(Luck and 
Gold, 2008; 
Lustig et al., 
2013b) 
 
 
Executive 
function  
Rule generation 
and control  
ID/ED task Reversal learning and  
Attentional Set shifting 
task  
(Gilmour et 
al., 2013; 
Young and 
Geyer, 2015)  
Working 
memory  
Goal maintenance 
and Interference 
control  
Goal 
maintenance  
 
 
 
Interference 
control 
Operant delayed non-
match to position task  
 
N-back task  
(Barch and 
Smith, 2008; 
Barch et al., 
2009; 
Dudchenko 
et al., 2013b) 
 
 
Long Term 
memory  
Reinforcement 
learning 
 
 
 
Declarative 
memory 
(Episodic 
memory) 
Probabilistic 
learning 
tasks 
 
 
Paired 
Associate 
learning (in 
CANTAB 
battery) 
Probabilistic learning 
 
No clear consensus  
Novel/Spontaneous 
object recognition –
not recommended 
Touchscreen Task:  
object-location paired-
associated learning  
Further development 
Ragland et al 
2009 
 
(Bussey, 
Barch and 
Baxter, 2013) 
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and validation 
recommended  
 
Social 
Cognition  
Acquisition and 
recognition of 
affective 
(emotional) states 
coupled to social 
recognition 
Tasks related 
to 
Identification 
of and 
response to 
emotional 
cues 
Social 
recognition/preference 
 
Recognition of 
multidimensional 
nature of social 
cognition and 
challenges of 
developing animal 
model. 
 
Further development 
and improvements 
recommended  
 
(Carter et al., 
2009; Millan 
and Bales, 
2013) 
 
 
 
 
Table 1. Tasks proposed by CNTRICS as possessing high construct validity and potential for 
further development.  The evidence for the translational capacity of the tasks is based upon 
the ability of the task to measure the construct of interest, that there is evidence that 
similar brain regions (and possibly brain networks) are recruited in the task and are 
impaired in schizophrenia.  From a pragmatic perspective, important considerations for 
inclusion by CNTRICS were the ability to standardize the tasks across laboratories and task 
reliability. In some cases, further development and validation is highlighted 
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Figure Legends: 
 
Fig 1. Framework for biomarker development through the adoption of forward and 
reverse translation approaches  
 
Fig Legend. The importance of adopting a reciprocal forward and reverse translation 
approach that is iteratively updated when additional new information is gained, either 
preclinically or clinically, offers the the greatest opportunity for discovering panels of 
biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Note that 
biomarkers are objective biological measures that can broadly be divided into several 
categories:  i) diagnostic - where they can aid in predicting risk and diagnosis  ii) prognostic - 
where they can provide a signpost for clinical course and iii) predictive of drug 
response/therapeutic intervention - whether beneficial or adverse, and thereby provide a 
potential means of patient stratification. 
 
